Posts tagged Mr. Ramakanth
HCW ups Verastem price target to $10

Roth Capital Partners reinitiated coverage of Flex Pharma (NASAQ:FLKS) with a “buy” rating and $14 price target. The stock closed at $3.37 on Sept. 6.

Read More